GlassScriptPhysician profile
Erica R Baumgartner
NPI 1801260898
$3,167.01
in general payments reported to CMS, 2019-2025
32 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $579 · 2023: $532 · 2024: $958 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,577 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,576.83 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $800.38 | 2022-2025 | |
| Novo Nordisk INC | $421.69 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $380.03 | 2022-2025 | Farxiga, Airsupra, Fasenra |
| Lilly USA, LLC | $200.62 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $131.21 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.72 | 2022-2025 | Jardiance, Ofev |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.24 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $105.91 | 2022-2025 | Bexsero, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $97.82 | 2024-2025 | |
| Astellas Pharma US INC | $89.45 | 2024-2025 | Veozah |
| Axsome Therapeutics, INC. | $87.35 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $65.40 | 2023-2025 | Glassia |
| Lundbeck LLC | $59.68 | 2025 | Rexulti |
| Amgen INC. | $55.69 | 2023-2025 | Tezspire, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $41.13 | 2023-2024 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $41.05 | 2022-2023 | Tyvaso |
| Corium, LLC | $38.79 | 2022-2025 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $38.24 | 2022 | |
| Exact Sciences Corporation | $29.66 | 2024-2025 | Cologuard Collection Kit |
| Covis Pharma Gmbh | $28.17 | 2022 | |
| Viatris Specialty LLC | $28.16 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $23.66 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $21.22 | 2025 | Gemtesa |
| Alnylam Pharmaceuticals INC. | $21.15 | 2024 | Onpattro |
| Jazz Pharmaceuticals INC. | $18.49 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.89 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.44 | 2022 | |
| Axonics, INC. | $14.94 | 2022 | |
| Antares Pharma, INC. | $14.55 | 2022 | |
| Harmony Biosciences LLC | $14.33 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.33 | 2024 | |
| Seqirus USA INC | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Baumgartner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.